Katabalo Deogratias M, Abraham Melina, Kidenya Benson R, Liwa Antony, Schroeder Kristin
Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.
Front Oncol. 2025 Feb 25;15:1444565. doi: 10.3389/fonc.2025.1444565. eCollection 2025.
Cancer chemotherapy is a treatment that systematically kills cancer cells but causes expected side effects, known as chemotherapy-induced toxicities. These toxicities are managed with supportive care medications. This study aimed to determine the prescription patterns of supportive care medications in children receiving chemotherapy at a major referral hospital in Tanzania.
A hospital-based descriptive cross-sectional study was conducted at Bugando Medical Centre (BMC). The study analyzed 104 prescription slips of pediatric cancer patients receiving chemotherapy and qualitatively assessed national guidelines and disease-specific protocols used in guiding treatment. Data were cleaned in Microsoft Excel, analyzed using STATA version 15, and presented as frequencies, percentages, and narrative summaries.
Ondansetron (84.6%) and pre-hydration normal saline (20.2%) were the most prescribed pre-chemotherapy supportive care medications. Similarly, oral ondansetron (80.8%) and post-hydration normal saline (22.1%) were the most prescribed post-chemotherapy medications. Few prescriptions included a combination of antiemetics, fluids, and proton pump inhibitors for regimens with multiple chemotherapeutic agents. National cancer treatment guidelines lacked detailed sections on supportive care medications, leaving prescribing decisions to clinicians, while Burkitt's lymphoma and nephroblastoma protocols offered more detailed guidance.
Antiemetics and hydration fluids dominated supportive care prescriptions. Significant gaps were identified in the inclusion of supportive care in national guidelines, with reliance on disease-specific protocols. These findings highlight the need for standardized, evidence-based supportive care guidelines tailored to resource-limited settings.
癌症化疗是一种系统性杀死癌细胞的治疗方法,但会引发预期的副作用,即化疗诱导的毒性反应。这些毒性反应通过支持性护理药物进行处理。本研究旨在确定坦桑尼亚一家主要转诊医院中接受化疗的儿童使用支持性护理药物的处方模式。
在布甘多医疗中心(BMC)开展了一项基于医院的描述性横断面研究。该研究分析了104份接受化疗的儿科癌症患者的处方单,并对用于指导治疗的国家指南和特定疾病方案进行了定性评估。数据在Microsoft Excel中进行清理,使用STATA 15版本进行分析,并以频率、百分比和叙述性总结的形式呈现。
昂丹司琼(84.6%)和化疗前预水化生理盐水(20.2%)是化疗前最常开具的支持性护理药物。同样,口服昂丹司琼(80.8%)和化疗后水化生理盐水(22.1%)是化疗后最常开具的药物。对于使用多种化疗药物的方案,很少有处方包括止吐药、液体和质子泵抑制剂的联合使用。国家癌症治疗指南缺乏关于支持性护理药物的详细章节,将处方决策留给临床医生,而伯基特淋巴瘤和肾母细胞瘤方案提供了更详细的指导。
止吐药和水化液在支持性护理处方中占主导地位。在国家指南中支持性护理的纳入方面发现了显著差距,依赖特定疾病方案。这些发现凸显了针对资源有限环境制定标准化、基于证据的支持性护理指南的必要性。